 (orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) Does AMPHOTERICIN B increase or decrease the risk of aplastic 
anemia?
 (orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.AGENT 
*(orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(recipient_message) FUNC: {
  "name": "recipient_message",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler",
    "content": "Does AMPHOTERICIN B increase the risk of aplastic anemia?"
  }
}
*(orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) Does AMPHOTERICIN B increase the risk of aplastic anemia?
 (orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) Does AMPHOTERICIN B increase the risk of aplastic anemia?
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_extracts) FUNC: {
  "name": "relevant_extracts",
  "to": "",
  "arguments": {
    "query": "Does AMPHOTERICIN B increase the risk of aplastic anemia?",
    "filter_drugs": [
      "AMPHOTERICIN B"
    ]
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_extracts) (=>          ) (X           )       (          ) 
        Below are some relevant extracts for your query:
        -----
        
CONTENT: AMPHOTERICIN B: adverse_reactions_table: <table width="100%"><col width="42%"/><col width="58%"/><tbody><tr><td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " 
valign="top"><paragraph><content styleCode="bold">Adverse Events <sup>a</sup>with an Incidence of &#x2265;3% (N=556) </content></paragraph></td></tr><tr><td styleCode="Lrule Botrule " 
valign="top"><paragraph><content styleCode="bold">Adverse Event</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph><content styleCode="bold">Percentage (%)
of Patients</content></paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Chills</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>18 AMPHOTERICIN B: 
adverse_reactions_table: </paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Fever</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>14</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Increased Serum Creatinine</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>11</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Multiple Organ Failure</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>11</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Nausea</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>9</paragraph></td></tr><tr><td AMPHOTERICIN B: adverse_reactions_table: styleCode="Lrule " valign="top"><paragraph>Hypotension</paragraph></td><td align="center" 
styleCode="Rrule " valign="top"><paragraph>8</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Respiratory Failure</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>8</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Vomiting</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>8</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Dyspnea</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>7</paragraph></td></tr><tr><td styleCode="Lrule " valign=" AMPHOTERICIN B: adverse_reactions_table: top"><paragraph>Sepsis</paragraph></td><td align="center" styleCode="Rrule "
valign="top"><paragraph>7</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Diarrhea</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>6</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Headache</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>6</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Cardiac Arrest</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>6</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Hypertension</paragraph></         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: clinical_pharmacology_table: Rrule " valign="top"><paragraph>290.0</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Lung</paragraph></td><td 
align="center" styleCode="Rrule " valign="top"><paragraph>222.0</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Liver</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>196.0</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Lymph Node</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>7. 
AMPHOTERICIN B: clinical_pharmacology_table: 6</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Kidney</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>6.9</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Heart 0</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>5.</paragraph></td></tr><tr><td styleCode="Botrule Lrule " valign="top"><paragraph>Brain</paragraph></td><td align="center" styleCode="Rrule Botrule " 
valign="top"><paragraph>1. AMPHOTERICIN B: clinical_pharmacology_table: 6</paragraph></td></tr></tbody></table>         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: openfda: package_ndc         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: openfda: generic_name         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: openfda: spl_id         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: openfda: spl_set_id         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: clinical_pharmacology: CLINICAL PHARMACOLOGY Pharmacokinetics The assay used to measure amphotericin B in the blood after the administration of ABELCET ® does not distinguish 
amphotericin B that is complexed with the phospholipids of ABELCET ® from amphotericin B that is uncomplexed. The pharmacokinetics of amphotericin B after the administration of ABELCET ® are 
nonlinear. Volume of distribution and clearance from blood increase with increasing dose of ABELCET ® , resulting in less than proportional increases in blood concentrations of amphotericin B over a 
dose range of 0.6-5 mg/kg/day. AMPHOTERICIN B: clinical_pharmacology: The pharmacokinetics of amphotericin B in whole blood after the administration of ABELCET ® and amphotericin B desoxycholate are: 
Pharmacokinetic Parameters of Amphotericin B in Whole Blood in Patients Administered Multiple Doses of ABELCET ® or Amphotericin B Desoxycholate Pharmacokinetic Parameter ABELCET ® 5 mg/kg/day for 5-7
days Mean ± SD Amphotericin B 0.6 mg/kg/day for 42 days a Mean ± SD Peak Concentration ( μg/mL) 1.7 ± 0.8 (n=10) b 1.1 ± 0.2 (n=5) Concentration at End of Dosing Interval (μg/mL) 0.6 ± 0.3 (n=10 b 0.4
± 0. AMPHOTERICIN B: clinical_pharmacology: 2 (n=5) Area Under Blood Concentration-Time Curve (AUC 0-24h ) (μg*h/mL) 14.0 ± 7.0 (n=14) b,c 17.1 ± 5 (n=5) Clearance (mL/h*kg) 436.0.± 188.5 (n=14) b,c 
38.0 ± 15 (n=5) Apparent Volume of Distribution (Vd area ) (L/kg) 131.0.± 57.7 (n=8) c 5.0.± 2.8 (n=5) Terminal Elimination Half-Life (h) 173.4 ± 78.0 (n=8) c 91.1 ± 40.9 (n=5) Amount Excreted in 
Urine Over 24 h After Last Dose (% of dose) d 0.         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: adverse_reactions_table: td><td align="center" styleCode="Rrule " valign="top"><paragraph>5</paragraph></td></tr><tr><td styleCode="Lrule " 
valign="top"><paragraph>Hypokalemia</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>5</paragraph></td></tr><tr><td styleCode="Lrule " 
valign="top"><paragraph>Infection</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>5</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Kidney 
Failure</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>5</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Pain</paragraph></td><td align="center" 
styleCode="R AMPHOTERICIN B: adverse_reactions_table: rule " valign="top"><paragraph>5</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Thrombocytopenia</paragraph></td><td 
align="center" styleCode="Rrule " valign="top"><paragraph>5</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Anemia</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>4</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Hyperbilirubinemia</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>4</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Gastrointestinal Hemorrhage</paragraph></td><td align="center" styleCode="Rrule AMPHOTERICIN B: 
adverse_reactions_table: " valign="top"><paragraph>4</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Leukopenia</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>4</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Rash</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>4</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Respiratory Disorder</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>4</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Chest Pain</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>3</ 
AMPHOTERICIN B: adverse_reactions_table: paragraph></td></tr><tr><td styleCode="Botrule Lrule " valign="top"><paragraph>Nausea and Vomiting</paragraph></td><td align="center" styleCode="Rrule Botrule 
" valign="top"><paragraph>3</paragraph></td></tr></tbody></table>         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: adverse_reactions: ADVERSE REACTIONS The total safety data base is composed of 921 patients treated with ABELCET ® (5 patients were enrolled twice and counted as separate 
patients), of whom 775 were treated with 5 mg/kg/day. Of these 775 patients, 194 patients were treated in four comparative studies; 25 were treated in open-label, non-comparative studies; and 556 
patients were treated in an open-label, emergency-use program. Most had underlying hematologic neoplasms, and many were receiving multiple concomitant medications. Of the 556 patients treated with 
ABELCET ® , 9% discontinued treatment due to adverse events regardless of presumed relationship to study drug. In general, the adverse events most commonly reported with ABELCET ® were transient 
chills and/or fever during infusion of the drug. AMPHOTERICIN B: adverse_reactions: Adverse Events a with an Incidence of ≥3% (N=556) Adverse Event Percentage (%) of Patients Chills 18 Fever 14 
Increased Serum Creatinine 11 Multiple Organ Failure 11 Nausea 9 Hypotension 8 Respiratory Failure 8 Vomiting 8 Dyspnea 7 Sepsis 7 Diarrhea 6 Headache 6 Cardiac Arrest 6 Hypertension 5 Hypokalemia 5 
Infection 5 Kidney Failure 5 Pain 5 Thrombocytopenia 5 Anemia 4 Hyperbilirubinemia 4 Gastrointestinal Hemorrhage 4 Leukopenia 4 Rash 4 Respiratory Disorder 4 Chest Pain 3 Nausea and Vomiting 3 a The 
causal association between these adverse events and ABELCET ® is uncertain. AMPHOTERICIN B: adverse_reactions: The following adverse events have also been reported in patients using ABELCET ® in 
open-label, uncontrolled clinical studies. The causal association between these adverse events and ABELCET ® is uncertain. Body as a whole: malaise, weight loss, deafness, injection site reaction 
including inflammation Allergic: bronchospasm, wheezing, asthma, anaphylactoid and other allergic reactions Cardiopulmonary: cardiac failure, pulmonary edema, shock, myocardial infarction, hemoptysis,
tachypnea, thrombophlebitis, pulmonary embolus, cardiomyopathy, pleural effusion, arrhythmias including ventricular fibrillation. AMPHOTERICIN B: adverse_reactions: Dermatological: maculopapular rash,
pruritus, exfoliative dermatitis, erythema multiforme Gastrointestinal: acute liver failure, hepatitis, jaundice, melena, anorexia, dyspepsia, cramping, epigastric pain, veno-occlusive liver disease, 
diarrhea, hepatomegaly, cholangitis, cholecystitis Hematologic: coagulation defects, leukocytosis, blood dyscrasias including eosinophilia Musculoskeletal: myasthenia, including bone, muscle, and 
joint pains Neurologic: convulsions, tinnitus, visual impairment, hearing loss, peripheral neuropathy, transient vertigo, diplopia, encephalopathy, cerebral vascular accident, extrapyramidal syndrome 
and other neurologic symptoms Urogenital: oliguria, decreased renal function, anuria, renal tubular acidosis, impotence, dysuria Serum electrolyte AMPHOTERICIN B: adverse_reactions: abnormalities: 
hypomagnesemia, hyperkalemia, hypocalcemia, hypercalcemia Liver function test abnormalities: increased AST, ALT, alkaline phosphatase, LDH Renal function test abnormalities: increased BUN Other test 
abnormalities: acidosis, hyperamylasemia, hypoglycemia, hyperglycemia, hyperuricemia, hypophosphatemia To report SUSPECTED ADVERSE REACTIONS, contact Leadiant Biosciences, Inc. at 1-888-393-4584 or by
email at drugsafety@leadiant.com or contact the FDA at 1-800-FDA-1088 or www.fda.gov/safety/medwatch.         
SOURCE:AMPHOTERICIN B label

        -----
        If NONE of the extracts are relevant, try doing a web search with the
        `relevant_search_extracts` tool/function-call
        
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE>
ANSWER: The provided extracts from the AMPHOTERICIN B label do not list aplastic anemia as an adverse reaction or side effect. The adverse reactions table and additional adverse reactions information 
mention various other side effects, but aplastic anemia is not mentioned. Therefore, based on the available information, there is no indication that AMPHOTERICIN B increases the risk of aplastic 
anemia.

SOURCE: AMPHOTERICIN B label
EXTRACT_START_END: Adverse Events with an Incidence... adverse_reactions: The following adverse events...
*(orchestrator-aplastic anemia-AMPHOTERICIN B)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) ANSWER: The provided extracts from the AMPHOTERICIN B label do not 
list aplastic anemia as an adverse reaction or side effect. The adverse reactions table and additional adverse reactions information mention various other side effects, but aplastic anemia is not 
mentioned. Therefore, based on the available information, there is no indication that AMPHOTERICIN B increases the risk of aplastic anemia.

SOURCE: AMPHOTERICIN B label
EXTRACT_START_END: Adverse Events with an Incidence... adverse_reactions: The following adverse events...
 (orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.USER  Entity.USER(Entity.USER) (=>       LLM) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>       LLM) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(final_answer) FUNC: {
  "name": "final_answer",
  "to": "",
  "arguments": {
    "question": "Does AMPHOTERICIN B increase or decrease the risk of aplastic anemia?",
    "steps": [
      "I asked FDAHandler whether AMPHOTERICIN B increases the risk of aplastic anemia.",
      "FDAHandler responded that the AMPHOTERICIN B label does not list aplastic anemia as an adverse reaction or side effect.",
      "Based on the information provided by FDAHandler, there is no indication that AMPHOTERICIN B increases the risk of aplastic anemia."
    ],
    "answer": "Based on the FDA label data, there is no indication that AMPHOTERICIN B increases the risk of aplastic anemia."
  }
}
*(orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.LLM  Entity.AGENT(final_answer) (=>          ) (X           )       (          ) __PASS__:Critic
 (orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.LLM  Entity.LLM(Entity.LLM) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-aplastic anemia-AMPHOTERICIN B)  FDAHandler  Entity.USER(FDAHandler) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (Critic)  Entity.USER  Entity.USER(          ) (=>    Critic) (X           )   FUNC(final_answer) FUNC: {
  "name": "final_answer",
  "to": "",
  "arguments": {
    "question": "Does AMPHOTERICIN B increase or decrease the risk of aplastic anemia?",
    "steps": [
      "I asked FDAHandler whether AMPHOTERICIN B increases the risk of aplastic anemia.",
      "FDAHandler responded that the AMPHOTERICIN B label does not list aplastic anemia as an adverse reaction or side effect.",
      "Based on the information provided by FDAHandler, there is no indication that AMPHOTERICIN B increases the risk of aplastic anemia."
    ],
    "answer": "Based on the FDA label data, there is no indication that AMPHOTERICIN B increases the risk of aplastic anemia.",
    "request": "final_answer"
  }
}
*(Critic)  Entity.AGENT  Entity.AGENT(final_answer) (=>          ) (X           )       (          ) 
        Question: Does AMPHOTERICIN B increase or decrease the risk of aplastic anemia?
        -----
        Reasoning:
        1. I asked FDAHandler whether AMPHOTERICIN B increases the risk of aplastic anemia.
2. FDAHandler responded that the AMPHOTERICIN B label does not list aplastic anemia as an adverse reaction or side effect.
3. Based on the information provided by FDAHandler, there is no indication that AMPHOTERICIN B increases the risk of aplastic anemia.
        -----
        Final answer: Based on the FDA label data, there is no indication that AMPHOTERICIN B increases the risk of aplastic anemia.
        
 (Critic)  Entity.USER 
 (Critic)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(Critic)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(  feedback) FUNC: {
  "name": "feedback",
  "to": "",
  "arguments": {
    "critique": "The reasoning provided is consistent with the information given by FDAHandler and follows a logical process. If the FDA label for AMPHOTERICIN B does not list aplastic anemia as an 
adverse reaction or side effect, it is reasonable to conclude that there is no known association between the drug and the condition. Therefore, there are no flaws in the reasoning presented."
  }
}
*(Critic)  Entity.LLM  Entity.AGENT(  feedback) (=>          ) (X           )       (          ) <DONE> __PASS__
*(orchestrator-aplastic anemia-AMPHOTERICIN B)  Critic  Entity.USER(    Critic) (=>     AGENT) (X           )   FUNC(  feedback) FUNC: {
  "name": "feedback",
  "to": "",
  "arguments": {
    "critique": "The reasoning provided is consistent with the information given by FDAHandler and follows a logical process. If the FDA label for AMPHOTERICIN B does not list aplastic anemia as an 
adverse reaction or side effect, it is reasonable to conclude that there is no known association between the drug and the condition. Therefore, there are no flaws in the reasoning presented.",
    "request": "feedback"
  }
}
*(orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.AGENT  Entity.AGENT(  feedback) (=>          ) (X           )       (          ) 
        Feedback: The reasoning provided is consistent with the information given by FDAHandler and follows a logical process. If the FDA label for AMPHOTERICIN B does not list aplastic anemia as an 
adverse reaction or side effect, it is reasonable to conclude that there is no known association between the drug and the condition. Therefore, there are no flaws in the reasoning presented.

        If any flaws in the reasoning used to produce your
        answer were identified, you must try again.
        
 (orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.USER 
 (orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-aplastic anemia-AMPHOTERICIN B)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE>

The final answer to the question "Does AMPHOTERICIN B increase or decrease the risk of aplastic anemia?" is that based on the FDA label data, there is no indication that AMPHOTERICIN B increases the 
risk of aplastic anemia. This conclusion is drawn from the information provided by FDAHandler, which states that the AMPHOTERICIN B label does not list aplastic anemia as an adverse reaction or side 
effect.
